 |
|
|
|||||||||
|
The DiaKine Management Team
Jerry L.
Nadler, M.D.,
KEITH IGNOTZ,
Mary Ann
Latona Nadler, Mary Ann Nadler has over 20 years of pharmaceutical and medical industry experience, primarily in the area of Regulatory Affairs. She was Director of Regulatory and Governmental Affairs for Adenosine Therapeutics. She was employed by NeXstar Pharmaceuticals as a Regulatory Affairs Project Manager and by International Medication Systems, Ltd. as Assistant Director/Clinical Programs Manager. Ms Nadler has successfully managed preparation and submission of INDs, NDAs, IDEs, PMAs and 510ks. Additionally, she has SBIR and STTR grant preparation and management experience with $3.2 million awarded under her direction. Ms. Nadler holds a Bachelor of Science degree in Microbiology and is a member of the Regulatory Affairs Professional Society and the Drug Information Association.
James B.
Farinholt, Jr., Mr. Farinholt has had an extensive career in the private and public sectors of finance and investment. He is a founder of Tall Oaks Capital, LP, a seed and early stage investment fund for life science, information technology and healthcare related companies. He served as the Company’s interim CEO until Mr. Ignotz was employed. Between 1992 and 2000, he was Special Assistant to the President at Virginia Commonwealth University. Prior to joining VCU, Mr. Farinholt had thirty years of experience in investment banking for small and medium-sized businesses as an executive officer at The Chase Bank in New York, in addition to Wheat First Union and Galleher & Company in Richmond, Virginia. Mr. Farinholt's public directorships are: PharmaNetics, Inc. (NASDAQ: PHAR), a theranostics company; and Owens & Minor, Inc. (NYSE: OMI), the nation’s leading distributor of name-brand medical/surgical supplies. He holds a B.S. degree from Hampden-Sydney College.
JACK W. SINGER,
Dr. Singer is a founder and Director of Cell Therapeutics, Inc. (CTI). He was appointed Chief Medical Officer in January 2004 and thereby became responsible for CTI’s clinical medical strategy. He is a noted expert in hematologic cancers. Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full member of the Fred Hutchinson Cancer Research Center. Between 1975 and 1992, he was Chief of Medical Oncology at the VA Medical Center in Seattle. Dr. Singer has served as an advisor to the NIH, has been a consultant to pharmaceutical companies and is a member of the Society for Clinical Investigation.
|
||||||||||
|
|
|
|
|
||||||||
|
©2006 DiaKine Therapeutics. All rights reserved.
|
|||||||||||
Jerry L. Nadler, MD
is Chief of Endocrinology and Metabolism at the University of
Virginia and Director of the Diabetes and Hormone Center of
Excellence. Dr. Nadler is recognized as a noted expert in the
pathogenesis of diabetes and related complications. He has been
conducting basic science and pre-clinical research on Lisofylline
and oral immune modulators for the past six years under grants
funded by sources including the Juvenile Diabetes Research
Foundation. Dr. Nadler has been invited to sit on major advisory
groups of the National Institutes of Health and the Juvenile
Diabetes Research Foundation. Dr. Nadler received his M.D. degree
from the University of Miami and additional specialized training at
the University of Southern California. He was the Director of
Diabetes and Endocrinology at the City of Hope National Medical
Center prior to coming to the University of
Virginia.
Keith Ignotz is a senior
corporate executive with over 25 years of experience in global
healthcare market and 14 of those in diabetes. He joined DiaKine from SpectRx, Inc., a
diabetes management company which he co-founded in 1993 and where he
served as President and Chief Operating Officer. While in that
position, he raised over $6.5 million in venture capital funding,
negotiated a $26.5 million strategic partnering collaboration and
brought the Company through an IPO. Previously,
he was President of Humphrey Instruments SmithKline Beckman (Japan)
and Humphrey Instruments (Germany), and Senior Vice
President of Allergan Humphrey. He has a B.A. from San Jose State
University and an M.B.A. from Pepperdine University.